Authors:
HH Wong, C Parkinson, JA Ledermann, JD Brenton, M Merger, A Shaw, A Patterson, M Shafi, HM Earl
Journal name: 
Gynecol Oncol Case Rep
Citation info: 
3:7-10
Abstract: 
► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.
DOI: 
http://doi.org/10.1016/j.gynor.2012.10.003
Research group: 
Brenton Group
E-pub date: 
31 Aug 2012